Abstract
This chapter will cover both common and uncommon non-pain symptoms associated with malignancies. Cancer-related fatigue (CRF) is described as a subjective sensation of tiredness out of proportion to any change in activity and severe enough to affect function. Cancer related may be a disorder of a sense of effort and central in origin. Exercise, corticosteroids, American ginseng, and psychostimulants may improve fatigue. Cachexia complex metabolic syndrome is characterized primarily by weight loss (5% weight loss over 6 months) which is most often accompanied by of muscle, adipose tissue, anorexia, anemia, and reduced physical function. The best treatment for cancer cachexia is cancer remission. There are no approved medications for the management of cachexia, and nutritional support alone is inadequate. Combinations of exercise, nutritional support, medications to stimulate appetite (e.g., megestrol acetate, olanzapine), and anti-inflammatories (e.g., celecoxib, omega-3 fatty acids) in small randomized trials have been found to improve outcomes. Mucositis from chemotherapy or radiation therapy is painful, interferes with nutritional intake, is associated with systemic infections and other complications, and increases the length of hospital stay and treatment costs. The evidence for treating mucositis is sparse. Pruritus is a sensation that provokes the desire to scratch. The behavior associated with pruritus extends to the desire to rub or pinch damaged skin with devices. Basic skin care is essential. Treatment of the underlying condition may also ameliorate pruritis. Treatment of the underlying condition may also ameliorate pruritis Lymphoma treatment quickly relieves pruritus related to Hodgkin’s disease and non-Hodgkin’s lymphoma. The classification of hiccups is based on duration. Hiccups are caused by coordinated contractions of intercostal muscle and diaphragm followed by a few milliseconds with involuntary closure of the glottis. Hiccups occur anywhere between 4 and 60 times a minute and can interfere with breathing, eating, and sleep, and can worsen pain, fatigue, weight loss, and dyspnea, dramatically reducing QOL. Pharmacologic management has centered on dopamine, GABA, and serotonin receptors. Dyspnea is a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that include inability to catch one’s breath, ineffective breathing, increased work of breathing, and chest tightness. The correlation of chest radiographic findings and spirometry to dyspnea is quite poor. Treating the underlying cause is the first line of therapy. Low doses of opioids, particularly morphine, and corticosteroid may reduce dyspnea in patients who are imminently dying. The core criteria for delirium comes from the DSM-IV and consists of disturbance of consciousness with loss of the ability to focus and shift attention. Half of patients undergoing hematopoietic stem cell transplants experience delirium during therapy, and the pretransplant risk factors are low cognitive functioning, lower physical functioning, higher creatinine, total body irradiation, older age, and prior alcohol or drug abuse. Prevention of delirium is more successful than treatment of delirium. Anxiety and depression are common symptoms which not only impair quality of life but also makes it difficult managing other symptoms such as pain and fatigue. When considering treatment for depression, both pharmacotherapy and psychotherapy are effective, especially in combination. Psychotherapy is recommended at all stages of depression or anxiety. When pharmacotherapy is considered, prognosis should be evaluated as many medications may take about 4 weeks to reach an effect. The multiplicity of symptoms that occur in advanced hematologic malignancies and other advanced blood disorders is a challenge to hematologists/oncologists. Consideration of palliative care consultation should be considered in patients with high symptom burden.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, Legrand SB, et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer. 2006;14(5):444–53.
Palm RF, Jim HSL, Boulware D, Johnstone PAS, Naghavi AO. Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma. Clin Transl Radiat Oncol. 2020;22:22–8.
McGee SF, Zhang T, Jonker H, Laurie SA, Goss G, Nicholas G, et al. The impact of baseline Edmonton symptom assessment scale scores on treatment and survival in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2018;19(1):e91–e9.
Hui D, Shamieh O, Paiva CE, Perez-Cruz PE, Kwon JH, Muckaden MA, et al. Minimal clinically important differences in the Edmonton symptom assessment scale in cancer patients: a prospective, multicenter study. Cancer. 2015;121(17):3027–35.
Selby D, Chakraborty A, Myers J, Saskin R, Mazzotta P, Gill A. High scores on the Edmonton symptom assessment scale identify patients with self-defined high symptom burden. J Palliat Med. 2011;14(12):1309–16.
Zeng L, Zhang L, Culleton S, Jon F, Holden L, Kwong J, et al. Edmonton symptom assessment scale as a prognosticative indicator in patients with advanced cancer. J Palliat Med. 2011;14(3):337–42.
Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton symptom assessment scale. Cancer. 2000;88(9):2164–71.
Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CC. Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton symptom assessment scale in cancer patients: a systematic review. J Pain Symptom Manag. 2013;45(6):1083–93.
Chang VT, Hwang SS, Kasimis B, Thaler HT. Shorter symptom assessment instruments: the condensed memorial symptom assessment scale (CMSAS). Cancer Investig. 2004;22(4):526–36.
Bircan HA, Yalcin GS, Fidanci S, Karaibrahimoglu A, Tuglu HC. The usefulness and prognostic value of memorial symptom assessment-short form and condensed memorial symptom assessment scale in assessment of lung cancer patients. Support Care Cancer. 2020;28(4):2005–14.
Ward JA, Balian C, Gilger E, Raybin JL, Li Z, Montgomery KE. Electronic symptom assessment in children and adolescents with advanced cancer undergoing hematopoietic stem cell transplantation. J Pediatr Oncol Nurs. 2020;37(4):255–64.
Gerlach C, Taylor K, Ferner M, Munder M, Weber M, Ramsenthaler C. Challenges in the cultural adaptation of the German myeloma patient outcome scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care. BMC Cancer. 2020;20(1):245.
Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned? Crit Rev Oncol Hematol. 2015;96(3):542–54.
Chow S, Wan BA, Pidduck W, Zhang L, DeAngelis C, Chan S, et al. Symptoms predictive of overall quality of life using the Edmonton symptom assessment scale in breast cancer patients receiving radiotherapy. Clin Breast Cancer. 2019;19(6):405–10.
McKenzie E, Zhang L, Chan S, Zaki P, Razvi Y, Tsao M, et al. Symptom correlates of dyspnea in advanced cancer patients using the Edmonton symptom assessment system. Support Care Cancer. 2020;28(1):87–98.
Merchant SJ, Brogly SB, Booth CM, Goldie C, Nanji S, Patel SV, et al. Palliative care and symptom burden in the last year of life: a population-based study of patients with gastrointestinal cancer. Ann Surg Oncol. 2019;26(8):2336–45.
Chen JJ, Huang SS, Li IF, Lin KP, Tsay SL. Prognostic association of demographic and clinical factors with the change rates of symptoms and depression among patients with hepatocellular carcinoma. Support Care Cancer. 2019;27(12):4665–74.
Berger A, et al. NCCN Guidelines Version 2.2019. Cancer-Related Fatigue 2019. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf.
Manitta V, Zordan R, Cole-Sinclair M, Nandurkar H, Philip J. The symptom burden of patients with hematological malignancy: a cross-sectional observational study. J Pain Symptom Manag. 2011;42(3):432–42.
Hjermstad MJ, Knobel H, Brinch L, Fayers PM, Loge JH, Holte H, et al. A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant. 2004;34(3):257–66.
Horsboel TA, Bultmann U, Nielsen CV, Nielsen B, Andersen NT, de Thurah A. Are fatigue, depression and anxiety associated with labour market participation among patients diagnosed with haematological malignancies? A prospective study. Psychooncology. 2015;24(4):408–15.
Wang XS. Pathophysiology of cancer-related fatigue. Clin J Oncol Nurs. 2008;12(5 Suppl):11–20.
Fukushima T, Nakano J, Ishii S, Natsuzako A, Kawachi H, Sakamoto J, et al. Influence of hemoglobin level on muscle and physical functions, activities of daily living, and quality of life in patients with hematological malignancies. Integr Cancer Ther. 2019;18:1534735419842196.
Ben-Arye E, Dahan O, Shalom-Sharabi I, Samuels N. Inverse relationship between reduced fatigue and severity of anemia in oncology patients treated with integrative medicine: understanding the paradox. Support Care Cancer. 2018;26(12):4039–48.
Monti M, Castellani L, Berlusconi A, Cunietti E. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manag. 1996;12(1):18–22.
Kripp M, Willer A, Schmidt C, Pilz LR, Gencer D, Buchheidt D, et al. Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors. Ann Hematol. 2014;93(2):317–25.
Morishita S, Kaida K, Tanaka T, Itani Y, Ikegame K, Okada M, et al. Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2012;20(12):3161–8.
Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122(3):477–85.
Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, et al. Clinical factors associated with fatigue in haematologic cancer patients receiving stem-cell transplantation. Eur J Cancer. 2006;42(12):1749–55.
Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, et al. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther. 2014;36(4):560–6.
Yang S, Chu S, Gao Y, Ai Q, Liu Y, Li X, et al. A narrative review of cancer-related fatigue (CRF) and its possible pathogenesis. Cell. 2019;8(7):738.
Filler K, Saligan LN. Defining cancer-related fatigue for biomarker discovery. Support Care Cancer. 2016;24(1):5–7.
Fernandez C, Firdous S, Jehangir W, Behm B, Mehta Z, Berger A, et al. Cancer-related fatigue: perception of effort or task failure? Am J Hosp Palliat Care. 2019;37:1049909119849420.
Renner M, Saligan LN. Understanding cancer-related fatigue: advancing the science. Fatigue. 2016;4(4):189–92.
Cai B, Allexandre D, Rajagopalan V, Jiang Z, Siemionow V, Ranganathan VK, et al. Evidence of significant central fatigue in patients with cancer-related fatigue during repetitive elbow flexions till perceived exhaustion. PLoS One. 2014;9(12):e115370.
Kisiel-Sajewicz K, Siemionow V, Seyidova-Khoshknabi D, Davis MP, Wyant A, Ranganathan VK, et al. Myoelectrical manifestation of fatigue less prominent in patients with cancer related fatigue. PLoS One. 2013;8(12):e83636.
Taylor JL, Todd G, Gandevia SC. Evidence for a supraspinal contribution to human muscle fatigue. Clin Exp Pharmacol Physiol. 2006;33(4):400–5.
McComas AJ, Miller RG, Gandevia SC. Fatigue brought on by malfunction of the central and peripheral nervous systems. Adv Exp Med Biol. 1995;384:495–512.
Gandevia SC, Allen GM, McKenzie DK. Central fatigue. Critical issues, quantification and practical implications. Adv Exp Med Biol. 1995;384:281–94.
Zhou ES, Hall KT, Michaud AL, Blackmon JE, Partridge AH, Recklitis CJ. Open-label placebo reduces fatigue in cancer survivors: a randomized trial. Support Care Cancer. 2019;27(6):2179–87.
Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, et al. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Support Care Cancer. 2015;23(6):1503–12.
Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3(7):961–8.
Oechsle K, Aslan Z, Suesse Y, Jensen W, Bokemeyer C, de Wit M. Multimodal exercise training during myeloablative chemotherapy: a prospective randomized pilot trial. Support Care Cancer. 2014;22(1):63–9.
Dimeo F, Schwartz S, Fietz T, Wanjura T, Boning D, Thiel E. Effects of endurance training on the physical performance of patients with hematological malignancies during chemotherapy. Support Care Cancer. 2003;11(10):623–8.
Arring NM, Barton DL, Brooks T, Zick SM. Integrative therapies for cancer-related fatigue. Cancer J. 2019;25(5):349–56.
Yennurajalingam S, Bruera E. Review of clinical trials of pharmacologic interventions for cancer-related fatigue: focus on psychostimulants and steroids. Cancer J. 2014;20(5):319–24.
Qu D, Zhang Z, Yu X, Zhao J, Qiu F, Huang J. Psychotropic drugs for the management of cancer-related fatigue: a systematic review and meta-analysis. Eur J Cancer Care (Engl). 2016;25(6):970–9.
Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.
Kaplan S, Goehring EL Jr, Melamed-Gal S, Nguyen-Khoa BA, Knebel H, Jones JK. Modafinil and the risk of cardiovascular events: findings from three US claims databases. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–90.
Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, et al. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–8.
Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of Cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336–51.
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.
Preston NJ, Hurlow A, Brine J, Bennett MI. Blood transfusions for anaemia in patients with advanced cancer. Cochrane Database Syst Rev. 2012;2012(2):CD009007.
Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;7:CD006704.
Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076–82.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.
Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016;75(2):188–98.
Ubachs J, Ziemons J, Minis-Rutten IJG, Kruitwagen R, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(6):1165–74.
Sasaki S, Oki E, Saeki H, Shimose T, Sakamoto S, Hu Q, et al. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-a). Int J Clin Oncol. 2019;24(10):1204–13.
Davis MP, Panikkar R. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med. 2019;8(1):86–101.
Tournadre A, Vial G, Capel F, Soubrier M, Boirie Y. Sarcopenia. Joint Bone Spine. 2019;86(3):309–14.
Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med. 2011;365(6):565–7.
Yavuzsen T, Walsh D, Davis MP, Kirkova J, Jin T, LeGrand S, et al. Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia. Support Care Cancer. 2009;17(12):1531–41.
Davis MP, Walsh D, Lagman R, Yavuzsen T. Early satiety in cancer patients: a common and important but underrecognized symptom. Support Care Cancer. 2006;14(7):693–8.
Davis MP, Dreicer R, Walsh D, Lagman R, LeGrand SB. Appetite and cancer-associated anorexia: a review. J Clin Oncol. 2004;22(8):1510–7.
Fearon KC, Barber MD, Falconer JS, McMillan DC, Ross JA, Preston T. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg. 1999;23(6):584–8.
Fearon KC, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg. 1998;227(2):249–54.
Mallard J, Gagez AL, Baudinet C, Herbinet A, Maury J, Bernard PL, et al. C-reactive protein level: a key predictive marker of cachexia in lymphoma and myeloma patients. J Hematol. 2019;8(2):55–9.
Frodin U, Lotfi K, Fomichov V, Juliusson G, Borjeson S. Frequent and long-term follow-up of health-related quality of life following allogeneic haematopoietic stem cell transplantation. Eur J Cancer Care (Engl). 2015;24(6):898–910.
Doney K, McMillen K, Buono L, Deeg HJ, Gooley T. Impact of body mass index on outcomes of hematopoietic stem cell transplantation in adults. Biol Blood Marrow Transplant. 2019;25(3):613–20.
Aoyama T, Yoshitsugu K, Fukaya M, Kume T, Kawashima M, Nakajima K, et al. Benefit of reducing body weight loss with a nutritional support pathway in patients undergoing allogeneic hematopoietic stem cell transplantation. Med Sci Monit Basic Res. 2019;25:187–98.
Kerby EH, Li Y, Getz KD, Smith EC, Smith LT, Bunin NJ, et al. Nutritional risk factors predict severe acute graft-versus-host disease and early mortality in pediatric allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2018;65(2):e26853.
DeFilipp Z, Troschel FM, Qualls DA, Li S, Kuklinski MW, Kempner ME, et al. Evolution of body composition following autologous and allogeneic hematopoietic cell transplantation: incidence of sarcopenia and association with clinical outcomes. Biol Blood Marrow Transplant. 2018;24(8):1741–7.
Silva P, Schmit D, Bonfim C, Campos DJ, Rabito EI, Vilela RM. Body composition of Fanconi anemia patients after hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter. 2017;39(4):318–24.
Cheney CL, Abson KG, Aker SN, Lenssen P, Cunningham BA, Buergel NS, et al. Body composition changes in marrow transplant recipients receiving total parenteral nutrition. Cancer. 1987;59(8):1515–9.
Cunningham BA, Morris G, Cheney CL, Buergel N, Aker SN, Lenssen P. Effects of resistive exercise on skeletal muscle in marrow transplant recipients receiving total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1986;10(6):558–63.
Argiles JM, Lopez-Soriano FJ, Busquets S. Mediators of cachexia in cancer patients. Nutrition. 2019;66:11–5.
Ebner N, Anker SD, von Haehling S. Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th cachexia conference. J Cachexia Sarcopenia Muscle. 2019;10(1):218–25.
Okabe Y, Sakata T, Kurokawa M, Fujimoto K, Ueda K, Masuno H, et al. Anorexia induced by toxohormone-L isolated from ascites fluid of patients with hepatoma. Physiol Behav. 1992;52(2):333–7.
Penna F, Ballaro R, Beltra M, De Lucia S, Garcia Castillo L, Costelli P. The skeletal muscle as an active player against cancer cachexia. Front Physiol. 2019;10:41.
Barkhudaryan A, Scherbakov N, Springer J, Doehner W. Cardiac muscle wasting in individuals with cancer cachexia. ESC heart Fail. 2017;4(4):458–67.
Roberts BM, Ahn B, Smuder AJ, Al-Rajhi M, Gill LC, Beharry AW, et al. Diaphragm and ventilatory dysfunction during cancer cachexia. FASEB J. 2013;27(7):2600–10.
Anderson LJ, Yin C, Burciaga R, Lee J, Crabtree S, Migula D, et al. Assessing cachexia acutely after autologous stem cell transplant. Cancers (Basel). 2019;11(9):1300.
Rief W, Mills PJ, Ancoli-Israel S, Ziegler MG, Pung MA, Dimsdale JE. Overnight changes of immune parameters and catecholamines are associated with mood and stress. Psychosom Med. 2010;72(8):755–62.
Trakada G, Kastritis E, Gavriatopoulou M, Velentza L, Fotiou D, Ziogas DC, et al. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Ann Hematol. 2019;98(6):1427–34.
Mendes NP, Barros TA, Rosa COB, Franceschini S. Nutritional screening tools used and validated for cancer patients: a systematic review. Nutr Cancer. 2019;71(6):898–907.
Dolan RD, Daly L, Sim WMJ, Fallon M, Ryan A, McMillan DC, et al. Comparison of the prognostic value of ECOG-PS, mGPS and BMI/WL: implications for a clinically important framework in the assessment and treatment of advanced cancer. Clin Nutr. 2019;39:2889.
McDonald JJ, Fallon MT, Laird BJA. Meaningful measures in cancer cachexia: implications for practice and research. Curr Opinion Support Palliative care. 2019;13(4):323–7.
Grundmann O, Yoon SL, Williams JJ. The value of bioelectrical impedance analysis and phase angle in the evaluation of malnutrition and quality of life in cancer patients--a comprehensive review. Eur J Clin Nutr. 2015;69(12):1290–7.
Davis MP, Yavuzsen T, Khoshknabi D, Kirkova J, Walsh D, Lasheen W, et al. Bioelectrical impedance phase angle changes during hydration and prognosis in advanced cancer. Am J Hosp Palliat Care. 2009;26(3):180–7.
Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38:2438.
Miura S, Naito T, Mitsunaga S, Omae K, Mori K, Inano T, et al. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol. BMC Cancer. 2019;19(1):528.
Argiles JM, Lopez-Soriano FJ, Stemmler B, Busquets S. Therapeutic strategies against cancer cachexia. Eur J Transl Myol. 2019;29(1):7960.
Shirai Y, Okugawa Y, Hishida A, Ogawa A, Okamoto K, Shintani M, et al. Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. Sci Rep. 2017;7(1):4826.
Ravasco P. Nutrition in cancer patients. J Clin Med. 2019;8(8):1211.
Gorjao R, Dos Santos CMM, Serdan TDA, Diniz VLS, Alba-Loureiro TC, Cury-Boaventura MF, et al. New insights on the regulation of cancer cachexia by N-3 polyunsaturated fatty acids. Pharmacol Ther. 2019;196:117–34.
Okamoto H, Shono K, Nozaki-Taguchi N. Low-dose of olanzapine has ameliorating effects on cancer-related anorexia. Cancer Manag Res. 2019;11:2233–9.
Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, et al. Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials). Curr Oncol Rep. 2016;18(6):37.
Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519–31.
Duncan M, Grant G. Oral and intestinal mucositis - causes and possible treatments. Aliment Pharmacol Ther. 2003;18(9):853–74.
Kasselberg AG, Orth DN, Gray ME, Stahlman MT. Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues. J Histochem Cytochem. 1985;33(4):315–22.
Fujisawa K, Miyamoto Y, Nagayama M. Basic fibroblast growth factor and epidermal growth factor reverse impaired ulcer healing of the rabbit oral mucosa. J Oral Pathol Med. 2003;32(6):358–66.
Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST. The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer. 2000;89(11):2258–65.
Schenck K, Schreurs O, Hayashi K, Helgeland K. The role of nerve growth factor (ngf) and its precursor forms in oral wound healing. Int J Mol Sci. 2017;18(2):386.
van Setten GB. Basic fibroblast growth factor in human saliva: detection and physiological implications. Laryngoscope. 1995;105(6):610–2.
da Fonseca MA. Management of mucositis in bone marrow transplant patients. J Dent Hyg. 1999;73(1):17–21.
McGuire DB, Yeager KA, Dudley WN, Peterson DE, Owen DC, Lin LS, et al. Acute oral pain and mucositis in bone marrow transplant and leukemia patients: data from a pilot study. Cancer Nurs. 1998;21(6):385–93.
Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 1993;72(5):1612–7.
Zerbe MB, Parkerson SG, Ortlieb ML, Spitzer T. Relationships between oral mucositis and treatment variables in bone marrow transplant patients. Cancer Nurs. 1992;15(3):196–205.
Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100(9 Suppl):2026–46.
Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol. 2009;63(2):239–51.
Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62(1):33–41.
Lambros MP, Parsa C, Mulamalla H, Orlando R, Lau B, Huang Y, et al. Identifying cell and molecular stress after radiation in a three-dimensional (3-D) model of oral mucositis. Biochem Biophys Res Commun. 2011;405(1):102–6.
Hong BY, Sobue T, Choquette L, Dupuy AK, Thompson A, Burleson JA, et al. Chemotherapy-induced oral mucositis is associated with detrimental bacterial dysbiosis. Microbiome. 2019;7(1):66.
Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, et al. Mucosal injury during anti-cancer treatment: from pathobiology to bedside. Cancer. 2019;11(6):857.
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995–2025.
Maria OM, Eliopoulos N, Muanza T. Radiation-induced Oral mucositis. Front Oncol. 2017;7:89.
Hong CHL, Gueiros LA, Fulton JS, Cheng KKF, Kandwal A, Galiti D, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27(10):3949–67.
Wilairat P, Kengkla K, Kaewpanan T, Kaewthong J, Ruankon S, Subthaweesin C, et al. Comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis in adult cancer patients: a systematic review and network meta-analysis. Eur J Hosp Pharm. 2020;27(2):103–10.
Bowen JM, Wardill HR. Advances in the understanding and management of mucositis during stem cell transplantation. Curr Opin Support Palliat Care. 2017;11(4):341–6.
Ariyawardana A, Cheng KKF, Kandwal A, Tilly V, Al-Azri AR, Galiti D, et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27(10):3985–95.
Okamoto K, Ninomiya I, Yamaguchi T, Terai S, Nakanuma S, Kinoshita J, et al. Oral cryotherapy for prophylaxis of oral mucositis caused by docetaxel, cisplatin, and fluorouracil chemotherapy for esophageal cancer. Esophagus: official journal of the Japan esophageal. Society. 2019;16(2):207–13.
Correa MEP, Cheng KKF, Chiang K, Kandwal A, Loprinzi CL, Mori T, et al. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2020;28(5):2449–56.
Sherr DL. Finding the magic in magic mouthwash. JAMA Intern Med. 2019;179(5):723–4.
Carnel SB, Blakeslee DB, Oswald SG, Barnes M. Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg. 1990;102(4):326–30.
Milazzo-Kiedaisch CA, Itano J, Dutta PR. Role of gabapentin in managing mucositis pain in patients undergoing radiation therapy to the head and neck. Clin J Oncol Nurs. 2016;20(6):623–8.
Kataoka T, Kiyota N, Shimada T, Funakoshi Y, Chayahara N, Toyoda M, et al. Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. Auris Nasus Larynx. 2016;43(6):677–84.
Bar AV, Weinstein G, Dutta PR, Dosoretz A, Chalian A, Both S, et al. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer. 2010;116(17):4206–13.
Bar AV, Weinstein G, Dutta PR, Chalian A, Both S, Quon H. Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. Head Neck. 2010;32(2):173–7.
Hermann GM, Iovoli AJ, Platek AJ, Wang C, Miller A, Attwood K, et al. A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer. Cancer. 2020;126(7):1480–91.
Elad S, Meidan I, Sellam G, Simaan S, Zeevi I, Waldman E, et al. Topical curcumin for the prevention of oral mucositis in pediatric patients: case series. Altern Ther Health Med. 2013;19(3):21–4.
Dos Reis PE, Ciol MA, de Melo NS, Figueiredo PT, Leite AF, Manzi NM. Chamomile infusion cryotherapy to prevent oral mucositis induced by chemotherapy: a pilot study. Support Care Cancer. 2016;24(10):4393–8.
Sahebjamee M, Mansourian A, Hajimirzamohammad M, Zadeh MT, Bekhradi R, Kazemian A, et al. Comparative efficacy of aloe vera and benzydamine mouthwashes on radiation-induced oral mucositis: a triple-blind, randomised, controlled clinical trial. Oral Health Prev Dent. 2015;13(4):309–15.
Liu TM, Luo YW, Tam KW, Lin CC, Huang TW. Prophylactic and therapeutic effects of honey on radiochemotherapy-induced mucositis: a meta-analysis of randomized controlled trials. Support Care Cancer. 2019;27(7):2361–70.
Zecha JA, Raber-Durlacher JE, Nair RG, Epstein JB, Sonis ST, Elad S, et al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support Care Cancer. 2016;24(6):2781–92.
Cronshaw M, Parker S, Anagnostaki E, Mylona V, Lynch E, Grootveld M. Photobiomodulation and oral mucositis: a systematic review. Dent J (Basel). 2020;8(3):87.
Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126:4423.
Zadik Y, Arany PR, Fregnani ER, Bossi P, Antunes HS, Bensadoun RJ, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019;27(10):3969–83.
Stander S. Chronic pruritus: principals of diagnostics and therapy. Hautarzt. 2007;58(7):627–36. quiz 37
Matterne U, Apfelbacher CJ, Loerbroks A, Schwarzer T, Buttner M, Ofenloch R, et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol. 2011;91(6):674–9.
Alizadeh N, Mirpour SH, Golmohamadi R, Darjani A, Eftekhari H, Rafiei R, et al. Chronic generalized pruritus without primary skin lesions: a longitudinal prospective observational study. Int J Dermatol. 2019;58(3):273–8.
Larson VA, Tang O, Stander S, Kang S, Kwatra SG. Association between itch and cancer in 16,925 patients with pruritus: experience at a tertiary care center. J Am Acad Dermatol. 2019;80(4):931–7.
Beigi M, Haberle M, Gschwendtner A, Baum U, Weisshaar E. Generalized chronic itch as a first sign of malignancy resembling paraneoplastic sensomotoric neuropathy. Acta Derm Venereol. 2018;98(5):526–7.
Song A, Gochoco A, Zhan T, Sahu J, Alpdogan O, Porcu P, et al. A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: reduction of disease burden and improvement in quality of life. J Am Acad Dermatol. 2020;83(1):78–85.
Bromberg H, Chang Y, Craig D. Pruritic manifestation of peripheral t cell lymphoma effectively managed with mirtazapine: a case report. J Pain Palliat Care Pharmacother. 2020;34(3):153–4.
Molloy K, Jonak C, Woei AJF, Guenova E, Busschots AM, Bervoets A, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the prospective cutaneous lymphoma international prognostic index (PROCLIPI) study. Br J Dermatol. 2020;182(3):770–9.
Luman W, Cull A, Palmer KR. Quality of life in patients stented for malignant biliary obstructions. Eur J Gastroenterol Hepatol. 1997;9(5):481–4.
Ballinger AB, McHugh M, Catnach SM, Alstead EM, Clark ML. Symptom relief and quality of life after stenting for malignant bile duct obstruction. Gut. 1994;35(4):467–70.
Elford AT, Dwyer JP, Fanning SB. Jaundice, hepatosplenomegaly, and portal lymphadenopathy in a middle-aged female: is it lymphoma? JGH Open. 2020;4(2):292–3.
Szepietowski JC, Salomon J. Uremic pruritus: still an important clinical problem. J Am Acad Dermatol. 2004;51(5):842–3.
Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky R, Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant. 1998;22(12):1179–83.
Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, et al. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol. 2016;43(9):787–91.
Kilic A, Gul U, Soylu S. Skin findings in internal malignant diseases. Int J Dermatol. 2007;46(10):1055–60.
Steinman HK, Greaves MW. Aquagenic pruritus. J Am Acad Dermatol. 1985;13(1):91–6.
Barnes HM, Sarkany I, Calnan CD. Pruritus and thyrotoxicosis. Trans St Johns Hosp Dermatol Soc. 1974;60(1):59–62.
Barrow MV, Bird ED. Pruritus in hyperthyroidism. Arch Dermatol. 1966;93(2):237–8.
Papathanasiou IV, Kelepouris K, Valari C, Papagiannis D, Tzavella F, Kourkouta L, et al. Depression, anxiety and stress among patients with hematological malignancies and the association with quality of life: a cross-sectional study. Med Pharm Rep. 2020;93(1):62–8.
Stander S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87(4):291–4.
Huang AH, Kaffenberger BH, Reich A, Szepietowski JC, Stander S, Kwatra SG. Pruritus associated with commonly prescribed medications in a tertiary care center. Medicine. 2019;6(3):84.
Peters J. Medication-related pruritis in older adults with long-term conditions. Br J Community Nurs. 2019;24(8):380–2.
Nocchi L, Roy N, D'Attilia M, Dhandapani R, Maffei M, Traista A, et al. Interleukin-31-mediated photoablation of pruritogenic epidermal neurons reduces itch-associated behaviours in mice. Nat Biomed Eng. 2019;3(2):114–25.
Tsuji M, Arai I, Miyagawa K, Miyagishi H, Saito A, Takeda K, et al. Involvement of interleukin-31 receptor a in morphine-induced itching and antinociception in mice. Eur J Pain. 2019;23(2):378–88.
Steinman HK, Kobza-Black A, Lotti TM, Brunetti L, Panconesi E, Greaves MW. Polycythaemia rubra vera and water-induced pruritus: blood histamine levels and cutaneous fibrinolytic activity before and after water challenge. Br J Dermatol. 1987;116(3):329–33.
Shah RA, Kowdley KV. Mechanisms and treatments of pruritus in primary biliary cholangitis. Semin Liver Dis. 2019;39(2):209–20.
Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Gimenez-Arnau AM, et al. European S2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99(5):469–506.
Krause K, Kessler B, Weller K, Veidt J, Chen SC, Martus P, et al. German version of ItchyQoL: validation and initial clinical findings. Acta Derm Venereol. 2013;93(5):562–8.
Lindh JD, Bradley M. Clinical effectiveness of moisturizers in atopic dermatitis and related disorders: a systematic review. Am J Clin Dermatol. 2015;16(5):341–59.
Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain. 2003;102(3):283–8.
Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1–7.
Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113(4):1264–9.
Kwatra SG, Stander S, Kang H. PD-1 blockade-induced pruritus treated with a mu-opioid receptor antagonist. N Engl J Med. 2018;379(16):1578–9.
Mozer-Glassberg Y, Hojsak I, Zevit N, Shapiro R, Shamir R. Pruritus responsive to naltrexone in a patient with cholestatic liver disease. Isr Medi Assoc J. 2011;13(2):111–2.
Mettang M, Weisshaar E. Pruritus: control of itch in patients undergoing dialysis. Skin Therapy Lett. 2010;15(2):1–5.
Reszke R, Szepietowski JC. End-stage renal disease chronic itch and its management. Dermatol Clin. 2018;36(3):277–92.
Razeghi E, Eskandari D, Ganji MR, Meysamie AP, Togha M, Khashayar P. Gabapentin and uremic pruritus in hemodialysis patients. Ren Fail. 2009;31(2):85–90.
Manenti L, Vaglio A, Costantino E, Danisi D, Oliva B, Pini S, et al. Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol. 2005;18(1):86–91.
Simonsen E, Komenda P, Lerner B, Askin N, Bohm C, Shaw J, et al. Treatment of uremic pruritus: a systematic review. Am J Kidney Dis. 2017;70(5):638–55.
Ataei S, Kord L, Larki A, Yasrebifar F, Mehrpooya M, Seyedtabib M, et al. Comparison of sertraline with rifampin in the treatment of cholestatic pruritus: a randomized clinical trial. Rev Recent Clin Trials. 2019;14(3):217–23.
Roulet T, Zdanowicz N. Delusional parasitosis treated by atypical antipsychotic and selective serotonin reuptake inhibitor: a case report. Psychiatr Danub. 2017;29(Suppl 3):219–21.
Greaves MW. Itch in systemic disease: therapeutic options. Dermatol Ther. 2005;18(4):323–7.
Gupta MA, Guptat AK. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol. 2001;15(6):512–8.
Khanna R, Boozalis E, Belzberg M, Zampella JG, Kwatra SG. Mirtazapine for the treatment of chronic pruritus. Medicine. 2019;6(3):73.
Kaur R, Sinha VR. Antidepressants as antipruritic agents: a review. Eur Neuropsychopharmacol. 2018;28(3):341–52.
Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: a systematic review. J Am Acad Dermatol. 2017;77(6):1068–73 e7.
Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55(3):543–4.
Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manag. 2003;25(3):288–91.
Rashid S, Trivedi DD, Al-Shathir M, Moulton M, Baumrucker SJ. Is there a role for 5-HT3 receptor antagonists in the treatment of opioid-induced pruritus? Am J Hosp Palliat Care. 2018;35(4):740–4.
Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998;10(10):865–70.
O'Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther. 2005;21(8):1041–5.
Swarna SS, Aziz K, Zubair T, Qadir N, Khan M. Pruritus associated with chronic kidney disease: a comprehensive literature review. Cureus. 2019;11(7):e5256.
Hussain AB, Samuel R, Hegade VS, Jones DE, Reynolds NJ. Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy. Br J Dermatol. 2019;181(6):1138–45.
Inan S, Torres-Huerta A, Jensen LE, Dun NJ. Yy a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. Eur J Pharmacol. 2019;864:172702.
Mercadante S. Opioid analgesics adverse effects: the other side of the coin. Curr Pharm Des. 2019;25(30):3197–202.
Tubog TD, Harenberg JL, Buszta K, Hestand JD. Prophylactic Nalbuphine to prevent Neuraxial opioid-induced pruritus: a systematic review and meta-analysis of randomized controlled trials. J Perianesth Nurs. 2019;34(3):491–501 e8.
Lewis JH. Hiccups: causes and cures. J Clin Gastroenterol. 1985;7(6):539–52.
Steger M, Schneemann M, Fox M. Systemic review: the pathogenesis and pharmacological treatment of hiccups. Aliment Pharmacol Ther. 2015;42(9):1037–50.
Kohse EK, Hollmann MW, Bardenheuer HJ, Kessler J. Chronic hiccups: an underestimated problem. Anesth Analg. 2017;125(4):1169–83.
Chang FY, Lu CL. Hiccup: mystery, nature and treatment. J Neurogastroenterol Motil. 2012;18(2):123–30.
Jeon YS, Kearney AM, Baker PG. Management of hiccups in palliative care patients. BMJ Support Palliat Care. 2018;8(1):1–6.
Woelk CJ. Managing hiccups. Can Fam Physician. 2011;57(6):672–5. e198-201
Gilbar P, McPherson I. Severe hiccups during chemotherapy: corticosteroids the likely culprit. J Oncol Pharm Pract. 2009;15(4):233–6.
Zhou JN, Huang XE, Ye Z, Li C, Zhang Q, Lin Y, et al. Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev. 2009;10(6):1147–50.
Forghieri F, Maccaferri M, Morselli M, Potenza L, Volzone F, Bandieri E, et al. Persistent hiccups as an adverse event to FLAG-IDA regimen for leukemia. Acta Oncol. 2009;48(6):932–3.
Takiguchi Y, Watanabe R, Nagao K, Kuriyama T. Hiccups as an adverse reaction to cancer chemotherapy. J Natl Cancer Inst. 2002;94(10):772.
Engleman EG, Lankton J, Lankton B. Granulated sugar as treatment for hiccups in conscious patients. N Engl J Med. 1971;285(26):1489.
Nausheen F, Mohsin H, Lakhan SE. Neurotransmitters in hiccups. Springerplus. 2016;5(1):1357.
Wang T, Wang D. Metoclopramide for patients with intractable hiccups: a multicentre, randomised, controlled pilot study. Intern Med J. 2014;44(12a):1205–9.
Zhang C, Zhang R, Zhang S, Xu M, Zhang S. Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial. Trials. 2014;15:295.
Curcic J, Schwizer A, Kaufman E, Forras-Kaufman Z, Banerjee S, Roy S, et al. Effects of baclofen on the functional anatomy of the oesophago-gastric junction and proximal stomach in healthy volunteers and patients with GERD assessed by magnetic resonance imaging and high-resolution manometry: a randomised controlled double-blind study. Aliment Pharmacol Ther. 2014;40(10):1230–40.
Holloway RH, Boeckxstaens GE, Penagini R, Sifrim D, Smout AJ. Objective definition and detection of transient lower esophageal sphincter relaxation revisited: is there room for improvement? Neurogastroenterol Motil. 2012;24(1):54–60.
Lehmann A, Hansson-Branden L, Karrberg L. Effects of repeated administration of baclofen on transient lower esophageal sphincter relaxation in the dog. Eur J Pharmacol. 2000;403(1–2):163–7.
Ozturk O, Yavuz E, Yazicioglu B, Uzuner B. Treatment of resistant idiopathic hiccups with pulse radio frequency on phrenic nerve and gabapentin: a case report. Niger J Clin Pract. 2017;20(7):910–3.
Ong AM, Tan CS, Foo MW, Kee TY. Gabapentin for intractable hiccups in a patient undergoing peritoneal dialysis. Perit Dial Int. 2008;28(6):667–8.
Tegeler ML, Baumrucker SJ. Gabapentin for intractable hiccups in palliative care. Am J Hosp Palliat Care. 2008;25(1):52–4.
Dong R, Xu X, Yu L, Ding H, Pan J, Yu Y, et al. Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. Aliment Pharmacol Ther. 2019;49(6):714–22.
Polito NB, Fellows SE. Pharmacologic interventions for intractable and persistent hiccups: a systematic review. J Emerg Med. 2017;53(4):540–9.
Adam E. A systematic review of the effectiveness of Oral baclofen in the Management of Hiccups in adult palliative care patients. J Pain Palliat Care Pharmacother. 2020;34(1):43–54.
Rouse S, Wodziak M. Intractable Hiccups. Curr Neurol Neurosci Rep. 2018;18(8):51.
Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999;159(1):321–40.
Banzett RBB, Sheridan AR, Baker KM, Lansing RW, Stevens JP. Scared to death' dyspnoea from the hospitalised patient's perspective. BMJ Open Pespir Res. 2020;7(1):e000493.
Bruera E, Schmitz B, Pither J, Neumann CM, Hanson J. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manag. 2000;19(5):357–62.
Arigliani M, Gupta A. Management of chronic respiratory complications in children and adolescents with sickle cell disease. Eur Respir Rev. 2020;29(157):200054.
Alameri HF, Aleem A, Kardas W, Jehangir A, Owais M, Al-Momen A. Dyspnea, pulmonary function and exercise capacity in adult Saudi patients with sickle cell disease. Saudi Med J. 2008;29(5):707–13.
Bosnak Guclu M, Bargi G, Sucak GT. Impairments in dyspnea, exercise capacity, physical activity and quality of life of allogeneic hematopoietic stem cell transplantation survivors compared with healthy individuals: a cross sectional study. Physiother Theory Pract. 2019;37:1–12.
Roberts MH, Mapel DW, Bruse S, Petersen H, Nyunoya T. Development of a modified BODE index as a mortality risk measure among older adults with and without chronic obstructive pulmonary disease. Am J Epidemiol. 2013;178(7):1150–60.
Ueno R, Nemoto M, Uegami W, Fukuoka J, Misawa M. Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: a radio-pathologic correlation. Respir Med Case Rep. 2019;26:168–70.
Tateishi A, Nakashima K, Hoshi K, Oyama Y, Ebisudani T, Misawa M, et al. Pulmonary tumor thrombotic Microangiopathy mimicking inhalation lung injury. Intern Med. 2019;58(9):1311–4.
Kazemi-Bajestani SMR, Becher H, Butts C, Basappa NS, Smylie M, Joy AA, et al. Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials. Support Care Cancer. 2019;27(4):1551–61.
Hecimovic A, Jakopovic M, Vukic Dugac A, Dzubur F, Samarzija M. Metastatic cancer mimics interstitial lung disease. Cases when we need fast diagnosis and treatment. Monaldi archives for chest disease. 2019;89(2)
Stana F, Vujovic M, Mayaki D, Leduc-Gaudet JP, Leblanc P, Huck L, et al. Differential regulation of the autophagy and proteasome pathways in skeletal muscles in sepsis. Crit Care Med. 2017;45(9):e971–e9.
Travers J, Dudgeon DJ, Amjadi K, McBride I, Dillon K, Laveneziana P, et al. Mechanisms of exertional dyspnea in patients with cancer. J Appl Physiol. 2008;104(1):57–66.
Sjoland H, Caidahl K, Karlson BW, Karlsson T, Herlitz J. Limitation of physical activity, dyspnea and chest pain before and two years after coronary artery bypass grafting in relation to sex. Int J Cardiol. 1997;61(2):123–33.
O'Donnell DE, Milne KM, James MD, de Torres JP, Neder JA. Dyspnea in COPD: new mechanistic insights and management implications. Adv Ther. 2020;37(1):41–60.
Reijnders T, Troosters T, Janssens W, Gosselink R, Langer D, Davenport PW, et al. Brain activations to Dyspnea in patients with COPD. Front Physiol. 2020;11:7.
Schon D, Dahme B, von Leupoldt A. Associations between the perception of dyspnea, pain, and negative affect. Psychophysiology. 2008;45(6):1064–7.
Nakai H, Tsujimoto K, Fuchigami T, Ohmatsu S, Osumi M, Nakano H, et al. Effect of anticipation triggered by a prior dyspnea experience on brain activity. J Phys Ther Sci. 2015;27(3):635–9.
von Leupoldt A, Sommer T, Kegat S, Baumann HJ, Klose H, Dahme B, et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med. 2008;177(9):1026–32.
Gandevia SC, Killian K, McKenzie DK, Crawford M, Allen GM, Gorman RB, et al. Respiratory sensations, cardiovascular control, kinaesthesia and transcranial stimulation during paralysis in humans. J Physiol. 1993;470:85–107.
Dudgeon DJ, Lertzman M, Askew GR. Physiological changes and clinical correlations of dyspnea in cancer outpatients. J Pain Symptom Manag. 2001;21(5):373–9.
Hui D, Morgado M, Vidal M, Withers L, Nguyen Q, Chisholm G, et al. Dyspnea in hospitalized advanced cancer patients: subjective and physiologic correlates. J Palliat Med. 2013;16(3):274–80.
Kuyucu T, Guclu SZ, Saylan B, Demir C, Senol T, Guner S, et al. A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberkuloz ve toraks. 2011;59(4):328–39.
Berliner D, Schneider N, Welte T, Bauersachs J. The differential diagnosis of Dyspnea. Dtsch Arztebl Int. 2016;113(49):834–45.
Morris NR, Sabapathy S, Adams L, Kingsley RA, Schneider DA, Stulbarg MS. Verbal numerical scales are as reliable and sensitive as visual analog scales for rating dyspnea in young and older subjects. Respir Physiol Neurobiol. 2007;157(2–3):360–5.
Farncombe M. Dyspnea: assessment and treatment. Support Care Cancer. 1997;5(2):94–9.
Persichini R, Gay F, Schmidt M, Mayaux J, Demoule A, Morelot-Panzini C, et al. Diagnostic accuracy of respiratory distress observation scales as surrogates of Dyspnea self-report in intensive care unit patients. Anesthesiology. 2015;123(4):830–7.
Hechtner M, Eichler M, Wehler B, Buhl R, Sebastian M, Stratmann J, et al. Quality of life in NSCLC survivors - a multicenter cross-sectional study. J Thorac Oncol. 2019;14(3):420–35.
Camargo LA, Pereira CA. Dyspnea in COPD: beyond the modified Medical Research Council scale. J Bras Pneumol. 2010;36(5):571–8.
Blinderman CD, Homel P, Billings JA, Portenoy RK, Tennstedt SL. Symptom distress and quality of life in patients with advanced congestive heart failure. J Pain Symptom Manag. 2008;35(6):594–603.
Pratter MR, Curley FJ, Dubois J, Irwin RS. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Arch Intern Med. 1989;149(10):2277–82.
Pratter MR, Abouzgheib W, Akers S, Kass J, Bartter T. An algorithmic approach to chronic dyspnea. Respir Med. 2011;105(7):1014–21.
Meriggi F. Dyspnea in cancer patients: a well-known and neglected symptom. Rev Recent Clin Trials. 2018;13(2):84–8.
Renier W, Winckelmann KH, Verbakel JY, Aertgeerts B, Buntinx F. Signs and symptoms in adult patients with acute dyspnea: a systematic review and meta-analysis. Eur J Emerg Med. 2018;25(1):3–11.
Hale ZE, Singhal A, Hsia RY. Causes of shortness of breath in the acute patient: a National Study. Acad Emerg Med. 2018;25(11):1227–34.
Masago K, Fujita S, Togashi Y, Irisa K, Sakamori Y, Hatachi Y, et al. Association between brain natriuretic peptide and distant metastases in advanced non-small cell lung cancer patients. Oncol Lett. 2011;2(2):253–6.
Wang XT, Liu DW, Zhang HM, Chai WZ. Integrated cardiopulmonary sonography: a useful tool for assessment of acute pulmonary edema in the intensive care unit. J Ultrasound Med. 2014;33(7):1231–9.
Volpicelli G, Silva F, Radeos M. Real-time lung ultrasound for the diagnosis of alveolar consolidation and interstitial syndrome in the emergency department. Eur J Emerg Med. 2010;17(2):63–72.
Frassi F, Gargani L, Tesorio P, Raciti M, Mottola G, Picano E. Prognostic value of extravascular lung water assessed with ultrasound lung comets by chest sonography in patients with dyspnea and/or chest pain. J Card Fail. 2007;13(10):830–5.
Uhlving HH, Buchvald F, Heilmann CJ, Nielsen KG, Gormsen M, Muller KG. Bronchiolitis obliterans after Allo-SCT: clinical criteria and treatment options. Bone Marrow Transplant. 2012;47(8):1020–9.
Wang X, Liu C, Wang M, Zhang YI, Li H, Liu G. Clinical features of post-infectious bronchiolitis obliterans in children undergoing long-term azithromycin treatment. Exp Ther Med. 2015;9(6):2379–83.
Ichikawa Y, Ninomiya H, Katsuki M, Hotta M, Tanaka M, Oizumi K. Low-dose/long-term erythromycin for treatment of bronchiolitis obliterans organizing pneumonia (BOOP). Kurume Med J. 1993;40(2):65–7.
Stover DE, Mangino D. Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia? Chest. 2005;128(5):3611–7.
Kako J, Kobayashi M, Oosono Y, Kajiwara K, Miyashita M. Immediate effect of fan therapy in terminal cancer with dyspnea at rest: a meta-analysis. Am J Hosp Palliat Care. 2020;37(4):294–9.
Ruangsomboon O, Dorongthom T, Chakorn T, Monsomboon A, Praphruetkit N, Limsuwat C, et al. High-flow nasal cannula versus conventional oxygen therapy in relieving dyspnea in emergency palliative patients with do-not-intubate status: a randomized crossover study. Ann Emerg Med. 2019;75:615.
Pisani L, Vega ML. Use of nasal high flow in stable COPD: rationale and physiology. COPD. 2017;14(3):346–50.
Pisani L, Fasano L, Corcione N, Comellini V, Musti MA, Brandao M, et al. Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. Thorax. 2017;72(4):373–5.
Nishimura M. High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects. Respir Care. 2016;61(4):529–41.
Wilson ME, Mittal A, Dobler CC, Curtis JR, Majzoub AM, Soleimani J, et al. High-flow nasal cannula oxygen in patients with acute respiratory failure and do-not-intubate or do-not-resuscitate orders: a systematic review. J Hosp Med. 2020;15(2):101–6.
Pisani L, Hill NS, Pacilli AMG, Polastri M, Nava S. Management of dyspnea in the terminally ill. Chest. 2018;154(4):925–34.
Vozoris NT. Opioids, chronic obstructive pulmonary disease, and hyperbole. J Palliat Med. 2018;21(6):745.
Dy SM GA, Waldfogel JM, Sharma R, Zhang A, Feliciano JL, Sedhom R, Day J, Gersten RA, Davidson PM, Bass EB. Interventions for breathlessness in patients with advanced cancer. Comparative Effectiveness Review No. 232. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No 290–2015-00006-I for the Agency for Healthcare Research and Quality and the Patient-Centered Outcomes Research Institute) AHRQ Publication No 21-EHC024, PCORI Publication No 2020-SR-01. 2020.
Strieder M, Pecherstorfer M, Kreye G. Symptomatic treatment of dyspnea in advanced cancer patients : a narrative review of the current literature. Wien Med Wochenschr. 2018;168(13–14):333–43.
Haywood A, Duc J, Good P, Khan S, Rickett K, Vayne-Bossert P, et al. Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults. Cochrane Database Syst Rev. 2019;2:CD012704.
Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, et al. Dexamethasone for dyspnea in cancer patients: a pilot double-blind, randomized, controlled trial. J Pain Symptom Manag. 2016;52(1):8–16 e1.
Dogan N, Tasci S. The effects of acupressure on quality of life and dyspnea in lung cancer: a randomized, controlled trial. Altern Ther Health Med. 2020;26(1):49–56.
Hernandez A, Bronas UG, Steffen AD, Marquez DX, Fritschi C, Quinn LT, et al. Rhythmic auditory stimulation increases 6-minute walk distance in individuals with COPD: a repeated measures study. Heart Lung. 2020;49:324.
Ratarasarn K, Kundu A. Yoga and tai chi: a mind-body approach in managing respiratory symptoms in obstructive lung diseases. Curr Opin Pulm Med. 2020;26(2):186–92.
Kanezaki M, Ebihara S. Effect of the cooling sensation induced by olfactory stimulation by L-menthol on dyspnoea: a pilot study. Eur Respir J. 2017;49(4):1601823.
Jackson P, Khan A. Delirium in critically ill patients. Crit Care Clin. 2015;31(3):589–603.
Siddiqi N, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006;35(4):350–64.
Maldonado JR. Acute brain failure: pathophysiology, diagnosis, management, and sequelae of delirium. Crit Care Clin. 2017;33(3):461–519.
Morandi A, Bellelli G. Delirium superimposed on dementia. Eur Geriatr Med. 2020;11(1):53–62.
Ljubisavljevic V, Kelly B. Risk factors for development of delirium among oncology patients. Gen Hosp Psychiatry. 2003;25(5):345–52.
Fann JR, Roth-Roemer S, Burington BE, Katon WJ, Syrjala KL. Delirium in patients undergoing hematopoietic stem cell transplantation. Cancer. 2002;95(9):1971–81.
Lawlor PG, Bush SH. Delirium diagnosis, screening and management. Curr Opin Support Palliat Care. 2014;8(3):286–95.
Leonard MM, Nekolaichuk C, Meagher DJ, Barnes C, Gaudreau JD, Watanabe S, et al. Practical assessment of delirium in palliative care. J Pain Symptom Manag. 2014;48(2):176–90.
Inouye SK, Foreman MD, Mion LC, Katz KH, Cooney LM Jr. Nurses' recognition of delirium and its symptoms: comparison of nurse and researcher ratings. Arch Intern Med. 2001;161(20):2467–73.
Maldonado JR. Delirium pathophysiology: an updated hypothesis of the etiology of acute brain failure. Int J Geriatr Psychiatry. 2018;33(11):1428–57.
Thom R, Silbersweig DA, Boland RJ. Major depressive disorder in medical illness: a review of assessment, prevalence, and treatment options. Psychosom Med. 2019;81(3):246–55.
Oldham MA, Flanagan NM, Khan A, Boukrina O, Marcantonio ER. Responding to ten common delirium misconceptions with best evidence: an educational review for clinicians. J Neuropsychiatr Clin Neurosci. 2018;30(1):51–7.
Choi SH, Lee H, Chung TS, Park KM, Jung YC, Kim SI, et al. Neural network functional connectivity during and after an episode of delirium. Am J Psychiatry. 2012;169(5):498–507.
Jones RN, Cizginer S, Pavlech L, Albuquerque A, Daiello LA, Dharmarajan K, et al. Assessment of instruments for measurement of delirium severity: a systematic review. JAMA Intern Med. 2019;179(2):231–9.
MacLullich AM, Shenkin SD, Goodacre S, Godfrey M, Hanley J, Stiobhairt A, et al. The 4 'A's test for detecting delirium in acute medical patients: a diagnostic accuracy study. Health Technol Assess. 2019;23(40):1–194.
Shenkin SD, Fox C, Godfrey M, Siddiqi N, Goodacre S, Young J, et al. Delirium detection in older acute medical inpatients: a multicentre prospective comparative diagnostic test accuracy study of the 4AT and the confusion assessment method. BMC Med. 2019;17(1):138.
Numan T, van den Boogaard M, Kamper AM, Rood PJT, Peelen LM, Slooter AJC, et al. Delirium detection using relative delta power based on 1-minute single-channel EEG: a multicentre study. Br J Anaesth. 2019;122(1):60–8.
Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669–76.
Hosie A, Phillips J, Lam L, Kochovska S, Noble B, Brassil M, et al. Multicomponent non-pharmacological intervention to prevent delirium for hospitalised people with advanced cancer: study protocol for a phase II cluster randomised controlled trial. BMJ Open. 2019;9(1):e026177.
Bush SH, Bruera E, Lawlor PG, Kanji S, Davis DH, Agar M, et al. Clinical practice guidelines for delirium management: potential application in palliative care. J Pain Symptom Manag. 2014;48(2):249–58.
Gaertner J, Eychmueller S, Leyhe T, Bueche D, Savaskan E, Schlogl M. Benzodiazepines and/or neuroleptics for the treatment of delirium in palliative care?-a critical appraisal of recent randomized controlled trials. Ann Palliat Med. 2019;8(4):504–15.
Shrikant KN. No reduction in delirium with the use of haloperidol or ziprasidone in critically ill patients. Am Fam Physician. 2019;99(7):460–1.
Riviere J, van der Mast RC, Vandenberghe J, Van Den Eede F. Efficacy and tolerability of atypical antipsychotics in the treatment of delirium: a systematic review of the literature. Psychosomatics. 2019;60(1):18–26.
Nikooie R, Neufeld KJ, Oh ES, Wilson LM, Zhang A, Robinson KA, et al. Antipsychotics for treating delirium in hospitalized adults: a systematic review. Ann Intern Med. 2019;171:485.
van der Vorst M, Neefjes ECW, Boddaert MSA, Verdegaal B, Beeker A, Teunissen SCC, et al. Olanzapine versus haloperidol for treatment of delirium in patients with advanced cancer: a phase III randomized clinical trial. Oncologist. 2019;25:e570.
Tenser RB. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2019;380(18):1778.
Shen YZ, Peng K, Zhang J, Meng XW, Ji FH. Effects of haloperidol on delirium in adult patients: a systematic review and meta-analysis. Med Princ Pract. 2018;27(3):250–9.
Vondeling AM, Knol W, Egberts TCG, Slooter AJC. Anticholinergic drug exposure at intensive care unit admission affects the occurrence of delirium. A prospective cohort study. Eur J Intern Med. 2020;78:121–6.
Lawley H, Hewison A. An integrative literature review exploring the clinical management of delirium in patients with advanced cancer. J Clin Nurs. 2017;26(23–24):4172–83.
Sun R, Wang S, Li S, Yang C, Zhao Y, Luo A. Effects of dexmedetomidine on delirium and mortality during sedation in ICU patients: a systematic review and meta-analysis protocol. BMJ Open. 2019;9(4):e025850.
Maagaard M, Barbateskovic M, Perner A, Jakobsen JC, Wetterslev J. Dexmedetomidine for the management of delirium in critically ill patients-a protocol for a systematic review. Acta Anaesthesiol Scand. 2019;63(4):549–57.
Marra A, McGrane TJ, Henson CP, Pandharipande PP. Melatonin in critical care. Crit Care Clin. 2019;35(2):329–40.
Foster J, Burry LD, Thabane L, Choong K, Menon K, Duffett M, et al. Melatonin and melatonin agonists to prevent and treat delirium in critical illness: a systematic review protocol. Syst Rev. 2016;5(1):199.
Alagiakrishnan K. Melatonin based therapies for delirium and dementia. Discov Med. 2016;21(117):363–71.
Baumgartner L, Lam K, Lai J, Barnett M, Thompson A, Gross K, et al. Effectiveness of melatonin for the prevention of intensive care unit delirium. Pharmacotherapy. 2019;39(3):280–7.
Hatta K, Kishi Y, Wada K, Takeuchi T, Odawara T, Usui C, et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014;71(4):397–403.
Sanford AM, Flaherty JH. Do nutrients play a role in delirium? Curr Opin Clin Nutr Metab Care. 2014;17(1):45–50.
Guo Y, Li Y, Zhang Y, Fang S, Xu X, Zhao A, et al. Post-operative delirium associated with metabolic alterations following hemi-arthroplasty in older patients. Age Ageing. 2019;49(1):88–95.
Crowley KE, Urben L, Hacobian G, Geiger KL. Valproic acid for the management of agitation and delirium in the intensive care setting: a retrospective analysis. Clin Ther. 2020;42:e65.
Yeo QM, Wiley TL, Smith MN, Hammond DA. Oral agents for the management of agitation and agitated delirium in critically ill patients. Crit Care Nurs Q. 2017;40(4):344–62.
Gagnon DJ, Fontaine GV, Riker RR, Fraser GL. Repurposing valproate, enteral clonidine, and phenobarbital for comfort in adult ICU patients: a literature review with practical considerations. Pharmacotherapy. 2017;37(10):1309–21.
Gagnon DJ, Fontaine GV, Smith KE, Riker RR, Miller RR 3rd, Lerwick PA, et al. Valproate for agitation in critically ill patients: a retrospective study. J Crit Care. 2017;37:119–25.
Sher Y, Miller Cramer AC, Ament A, Lolak S, Maldonado JR. Valproic acid for treatment of hyperactive or mixed delirium: rationale and literature review. Psychosomatics. 2015;56(6):615–25.
Asadollahi S, Heidari K, Hatamabadi H, Vafaee R, Yunesian S, Azadbakht A, et al. Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial. Int Clin Psychopharmacol. 2015;30(3):142–50.
Potharajaroen S, Tangwongchai S, Tayjasanant T, Thawitsri T, Anderson G, Maes M. Bright light and oxygen therapies decrease delirium risk in critically ill surgical patients by targeting sleep and acid-base disturbances. Psychiatry Res. 2018;261:21–7.
Estrup S, Kjer CKW, Poulsen LM, Gogenur I, Mathiesen O. Delirium and effect of circadian light in the intensive care unit: a retrospective cohort study. Acta Anaesthesiol Scand. 2018;62(3):367–75.
Krebber AM, Buffart LM, Kleijn G, Riepma IC, de Bree R, Leemans CR, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psycho-Oncology. 2014;23(2):121–30.
Block SD. Psychological issues in end-of-life care. J Palliat Med. 2006;9(3):751–72.
Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, et al. Concise health risk tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011;72(6):757–64.
Amonoo HL, Fenech A, Greer JA, Temel JS, Huffman JC, El-Jawahri A. Does desire to pursue pleasurable activities matter? The impact of pretransplantation anhedonia on quality of life and fatigue in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(8):1477–81.
Fujisawa D. Depression in cancer care. Keio J Med. 2018;67(3):37–44.
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;12:CD006528.
Barbosa MG, Delfino RS, Sarin LM, Jackowski AP. Repeated subcutaneous esketamine administration for depressive symptoms and pain relief in a terminally ill cancer patient: a case report. Palliat Med. 2020;34(6):822–5.
Falk E, Schlieper D, van Caster P, Lutterbeck MJ, Schwartz J, Cordes J, et al. A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study. BMC Palliat Care. 2020;19(1):1.
Tremblay A, Breitbart W. Psychiatric dimensions of palliative care. Neurol Clin. 2001;19(4):949–67.
Lloyd-Williams M, Friedman T, Rudd N. An analysis of the validity of the hospital anxiety and depression scale as a screening tool in patients with advanced metastatic cancer. J Pain Symptom Manag. 2001;22(6):990–6.
Reuben DB, Mor V. Nausea and vomiting in terminal cancer patients. Arch Intern Med. 1986;146(10):2021–3.
Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. Br Med J. 1979;1(6174):1323–4.
Gao S, Zhang M, Wu K, Zhu J, He Z, Li J, et al. Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(5):617–23.
Di Renzo N, Musso M, Scime R, Cupri A, Perrone T, De Risi C, et al. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant. 2020;55:2114.
Tendas A, Marchesi F, Mengarelli A, Annibali O, Tomarchio V, Saltarelli D, et al. Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Support Care Cancer. 2019;27(3):793–803.
Crossnohere NL, Richardson DR, Reinhart C, O'Donoghue B, Love SM, Smith BD, et al. Side effects from acute myeloid leukemia treatment: results from a national survey. Curr Med Res Opin. 2019;35(11):1965–70.
Rizio AA, White MK, McCausland KL, Quock TP, Guthrie SD, Yokota M, et al. Treatment tolerability in patients with immunoglobulin light-chain amyloidosis. Am Health Drug Benefits. 2018;11(8):430–7.
Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat. 2013;142(1):101–7.
Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19(10):1533–8.
Morrow GR. Susceptibility to motion sickness and the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy. Cancer Treat Rep. 1984;68(9):1177–8.
Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14(4):348–53.
Hui D, Bruera E. The Edmonton symptom assessment system 25 years later: past, present, and future developments. J Pain Symptom Manag. 2017;53(3):630–43.
Cheng AW, Abdeljaber M, Lima NA, Shebrain S. Large bowel obstruction in the setting of small lymphocytic lymphoma. Cureus. 2020;12(8):e9640.
Kasparian S, Burns E, Shehabeldin A, Awar M, Pingali SR. Recurrent small bowel obstruction caused by Burkitt lymphoma in an elderly man: a case report and review of the literature. J Med Case Rep. 2020;14(1):127.
Shirwaikar Thomas A, Schwartz M, Quigley E. Gastrointestinal lymphoma: the new mimic. BMJ Open Gastroenterol. 2019;6(1):e000320.
Menke DM, Kyle RA, Fleming CR, Wolfe JT 3rd, Kurtin PJ, Oldenburg WA. Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc. 1993;68(8):763–7.
Coluzzi F, Rolke R, Mercadante S. Pain management in patients with multiple myeloma: an update. Cancers (Basel). 2019;11(12):2037.
Sloot S, Boland J, Snowden JA, Ezaydi Y, Foster A, Gethin A, et al. Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study. Support Care Cancer. 2015;23(3):671–8.
Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006;23(3):229–35.
Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19(9):2542–54.
Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019;27(1):87–95.
Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. Support Care Cancer. 2005;13(2):80–4.
Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, et al. 2016 updated MASCC/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer. 2017;25(1):271–5.
Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261–8.
Aapro M, Zhang L, Yennu S, LeBlanc TW, Schwartzberg L. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective. Future Oncol. 2019;15(10):1067–84.
Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134–42.
Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, et al. NCCN guidelines insights: antiemesis, Version 2.2017. J Natl Compr Cancer Netw. 2017;15(7):883–93.
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:JCO2001296.
Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25(1):277–88.
Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017;25(1):303–8.
Hardy J, Skerman H, Glare P, Philip J, Hudson P, Mitchell G, et al. A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer. 2018;18(1):510.
Davis MP, Hallerberg G. Palliative medicine study group of the multinational association of supportive care in c. a systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manag. 2010;39(4):756–67.
Navari RM, Pywell CM, Le-Rademacher JG, White P, Dodge AB, Albany C, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial. JAMA Oncol. 2020;6(6):895–9.
Davis MP. Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Cancer Netw. 2016;14(7):915–22.
Winston AW, Rinehart RS, Riley GP, Vacchiano CA, Pellegrini JE. Comparison of inhaled isopropyl alcohol and intravenous ondansetron for treatment of postoperative nausea. AANA J. 2003;71(2):127–32.
Verma DK, Bansal S, Sharma P, Sundararaman P. Control of postoperative nausea and vomiting in oral and maxillofacial surgery patients with isopropyl alcohol: a prospective randomized clinical trial. J Maxillofac Oral Surg. 2018;17(4):576–81.
Teran L, Hawkins JK. The effectiveness of inhalation isopropyl alcohol vs. granisetron for the prevention of postoperative nausea and vomiting. AANA J. 2007;75(6):417–22.
Schwartz A. Comparison of inhalation of isopropyl alcohol vs promethazine in the treatment of postoperative nausea and vomiting (PONV) in patients identified as high risk for developing PONV. AANA J. 2009;77(6):417–8. author reply 8
Radford KD, Fuller TN, Bushey B, Daniel C, Pellegrini JE. Prophylactic isopropyl alcohol inhalation and intravenous ondansetron versus ondansetron alone in the prevention of postoperative nausea and vomiting in high-risk patients. AANA J. 2011;79(4 Suppl):S69–74.
Pellegrini J, DeLoge J, Bennett J, Kelly J. Comparison of inhalation of isopropyl alcohol vs promethazine in the treatment of postoperative nausea and vomiting (PONV) in patients identified as at high risk for developing PONV. AANA J. 2009;77(4):293–9.
Beadle KL, Helbling AR, Love SL, April MD, Hunter CJ. Isopropyl alcohol nasal inhalation for nausea in the emergency department: a randomized controlled trial. Ann Emerg Med. 2016;68(1):1–9 e1.
Dupuis LL, Roscoe JA, Olver I, Aapro M, Molassiotis A. 2016 updated MASCC/ESMO consensus recommendations: anticipatory nausea and vomiting in children and adults receiving chemotherapy. Support Care Cancer. 2017;25(1):317–21.
Zeltzer LK, Dolgin MJ, LeBaron S, LeBaron C. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics. 1991;88(1):34–42.
Varejao CDS, Santo F. Laser acupuncture for relieving nausea and vomiting in pediatric patients undergoing chemotherapy: a single-blind randomized clinical trial. J Pediatr Oncol Nurs. 2019;36(1):44–54.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Davis, M., Fernandez, C., Vithalani, N., Nicholls, L.E., Digwood, G. (2023). Symptoms in Advanced Hematologic Malignancies and Other Serious Hematologic Conditions. In: Ullrich, C.K., Roeland, E.J. (eds) Palliative Care in Hematologic Malignancies and Serious Blood Disorders. Springer, Cham. https://doi.org/10.1007/978-3-031-38058-7_14
Download citation
DOI: https://doi.org/10.1007/978-3-031-38058-7_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-38057-0
Online ISBN: 978-3-031-38058-7
eBook Packages: MedicineMedicine (R0)